Clopidogrel Duration After Coronary Stent Implantation

Drug‑Eluting Stents (DES)

Patients receiving drug‑eluting stents should be prescribed clopidogrel 75 mg daily for a minimum of 12 months, regardless of whether the indication is acute coronary syndrome or stable coronary disease (Class I, Level B). 1, 2, 3, 4, 5
The 12‑month minimum applies to all contemporary DES platforms, including sirolimus‑eluting and paclitaxel‑eluting stents. (Class I, Level B). 1, 2, 6
Extending clopidogrel beyond 12 months may be considered in selected patients (Class IIb, Level C). 3, 7

After BMS implantation, clopidogrel should be continued for at least 1 month. (Class I, Level B). 1, 2, 8, 4, 5
Ideally, therapy should be extended up to 12 months unless the patient has a high bleeding risk; in such cases a minimum of 2 weeks is acceptable before switching to aspirin monotherapy. (Class I, Level B). 1, 2, 8, 4, 5

All ACS patients receiving any stent (DES or BMS) should receive clopidogrel for ≥12 months, with alternative options of prasugrel 10 mg daily or ticagrelor 90 mg twice daily (Class I, Level B). 4, 5

For stable coronary disease treated with DES, the 12‑month clopidogrel duration remains the standard (Class I, Level B). 4, 5
For stable disease treated with BMS, a minimum of 1 month is required, with an ideal target of 12 months when bleeding risk permits (Class I, Level B). 4, 5

When bleeding risk outweighs thrombotic benefit, earlier discontinuation (<12 months) is reasonable (Class IIa, Level C). 4, 5
In high‑bleeding‑risk patients with BMS, a minimum of 2 weeks of clopidogrel is acceptable before transitioning to aspirin alone. (Class I, Level B). 1, 2, 8, 4

Aspirin must be continued indefinitely alongside clopidogrel during dual antiplatelet therapy (DAPT). (Class I, Level B). 1, 2, 6, 3
Initial aspirin dosing:
- 162–325 mg daily for 1 month after BMS,
- 162–325 mg daily for 3 months after sirolimus‑eluting DES,
- 162–325 mg daily for 6 months after paclitaxel‑eluting DES,
After completing the prescribed clopidogrel course, aspirin monotherapy (75–162 mg daily) should be continued indefinitely. (Class I, Level B). 1, 2, 6

Outcome	Effect of Prolonged DAPT (>12 mo)	Evidence
Stent thrombosis	Reduced (≈3 fewer events per 1,000 patients per year)	[12]
Myocardial infarction	Reduced (≈6 fewer events per 1,000 patients per year)	[12]
Major bleeding	Increased (≈5 more events per 1,000 patients per year)	[12]
Overall odds ratio for major bleeding	1.58 (95 % CI 1.20–2.09)	[12]

A 2016 ACC/AHA systematic review concluded that extending DAPT beyond 12 months decreases stent thrombosis and myocardial infarction but increases major bleeding (OR 1.58, 95 % CI 1.20‑2.09). (Class IIa, Level B). 12